India's Formulation Push: Solubility, Stability, Smarter Pills

The problems being solved

India’s pharmaceutical engine, the world’s largest supplier of generic medicines, runs on a bedrock of formulation science. Yet the molecules coming down the pipeline are increasingly difficult to work with. The core challenges are not new, but they are intensifying as drug candidates grow more complex and patient expectations rise.

Poor water solubility tops the list. A large fraction of new chemical entities and many established generics barely dissolve in the gut, leaving bioavailability stubbornly low. Innovators are not just battling a physicochemical quirk; they are trying to rescue entire therapeutic classes from sub-optimal absorption.

Stability is the silent killer of shelf life. Formulations degrade, impurities creep in, and the delicate balance of excipients can tip during storage. In a country where medicines travel long distances through heat and humidity, room-temperature stability is a hard requirement, not a nice-to-have.

Patient compliance is the human face of formulation. Swallowing a tablet is a daily struggle for the elderly, children, and those with dysphagia. Bitter tastes make pediatric doses a battle. Frequent dosing erodes adherence. The problem is as much about behavior as it is about biology.

Controlled release adds another layer. Many drugs need to stay in the stomach longer, release over hours, or bypass the stomach entirely. Short gastric residence times and variable pH environments defeat conventional tablets. Manufacturing itself throws up hurdles: inconsistent granulation, costly multi-step processes, and the ever-present need to keep production simple and reproducible.

How the field is solving it

The response is a quiet revolution in excipient science and process engineering. Solid dispersions are a frontline weapon against poor solubility. By embedding a drug in a polymer matrix—PVPK-30, copovidone, PEG 6000—innovators force the crystalline drug into an amorphous state, dramatically boosting dissolution. Spray-drying and hot-melt extrusion are turning this into a reproducible industrial art.

Particle engineering takes a different route. Liquisolid systems load a liquid drug onto a porous carrier like dietary cellulose wheat fibers, creating a free-flowing powder that dissolves fast. Cyclodextrin inclusion complexes cage the drug molecule at a molecular level, while simple salt formation with long-chain fatty acids can transform solubility without exotic equipment.

Stability is being engineered into the formula itself. Specific antioxidant combinations suppress nitrosamine formation in extended-release products. Citric acid as a stabilizing agent lets certain formulations sit at room temperature. Lyophilization—freeze-drying—locks in the structure of fragile iron complexes for injectables.

Patient-centric design is where empathy meets technology. Orodispersible tablets that melt in the mouth in seconds are tackling dysphagia. Taste masking with ion-exchange resins binds bitter drugs until they pass the taste buds. Oral films and buccal sprays bypass first-pass metabolism and offer a discreet, rapid onset that tablets cannot match.

Controlled release is moving beyond simple matrix tablets. Floating systems use oil entrapment and mucoadhesive polymers to keep a dosage form buoyant in the stomach for hours. Osmotic pump tablets deliver a zero-order release profile, independent of gut conditions. Multi-compartment tablets layer immediate and sustained release in a single pill, reducing dosing frequency.

On the manufacturing floor, the push is for elegant simplicity. Direct compression eliminates wet granulation steps, cutting time and cost. Optimized granulation parameters—sieve sizes, mixing times—are being dialed in for consistent, scalable output.

Where the market is heading

The global drug formulation market is approaching the low trillions of dollars by 2026, with oral dosage forms holding a commanding share of over two-fifths of the total (Future Market Insights). The formulation development outsourcing segment alone is a multi-billion-dollar opportunity, expanding at a high-single-digit annual clip as pharma companies lean on CDMOs for complex development work (Grand View Research).

India is the fastest-growing country in this landscape, with a projected growth rate in the mid-single digits annually through 2036 (Future Market Insights). The country already supplies roughly a fifth of the world’s generics, and its pharmaceutical exports could grow ten- to fifteen-fold to nearly USD 350 billion by 2047, driven by a deliberate shift from volume generics to value-added innovative therapies and biosimilars (Bain & Company).

Several currents are reshaping demand. Patient-centric dosage forms and specialty pharmaceuticals are no longer niche—they are becoming the expectation. The adoption of AI and digital tools in formulation optimization is accelerating, helping researchers screen excipient combinations and predict stability faster than ever. Government schemes like the Production Linked Incentive (PLI) and PMBJP are channeling investment into domestic R&D and manufacturing capacity, reinforcing India’s ambition to move up the value chain.

The white space

The most fertile ground lies at the intersection of problems. Combining solubility enhancement with patient-friendly formats—an amorphous solid dispersion in an orodispersible tablet, for example—remains an open design space. Platform technologies that can stabilize multiple drugs with a single excipient backbone would slash development time for complex generics.

Controlled release for gastroretentive and osmotic systems is still under-exploited for drugs beyond the usual suspects. There is room for cost-effective, directly compressible floating formulations that do not require specialized equipment. Taste masking that works across a wide pH range and does not compromise dissolution is another unsolved puzzle.

India’s vast CDMO ecosystem and its growing expertise in biologics and biosimilars open a white space for formulation services that bridge small molecules and large molecules. AI-driven formulation design, still in its early days, could become a differentiator for companies that build proprietary datasets around Indian patient populations and stability conditions.

Finally, the push toward value-driven exports creates demand for differentiated dosage forms—oral films, sublingual tablets, multi-layer release systems—that can command a premium in regulated markets. The opportunity is not just to make medicines cheaper, but to make them smarter.

Explore the innovators

The inventors, patents, and companies driving these formulation advances in India can be explored on Deeptech Navigator. From solid dispersion pioneers to oral film developers, the ecosystem is rich with problem-solvers who are redefining how medicines are made and taken. Dive into the specific technologies, the people behind them, and the patent landscape that maps the future of pharmaceutical formulation.

In our data

Sources

• Pharmaceutical Formulation Development: Principles & Process ↗
• The art and science of drug formulation | Article ↗
• Pharmaceutical Formulation - an overview ↗
• Understanding the pharmaceutical value chain ↗
• A comprehensive guide to the pharmaceutical supply chain ↗
• Pharma Supply Chain: A Comprehensive Guide ↗
• Pharmaceutical Market Size, Share and Trends 2026 to 2035 ↗
• Formulation Development Outsourcing Market (2025 - 2030) ↗